Business Wire

European observational study SANTORINI shows LDL-C levels remain higher than recommended goals and combination therapies are under-utilised in patients at very high or high cardiovascular risk

Share

Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) announced today inaugural data from SANTORINI, the first European observational study since the 2019 ESC/EAS management of dyslipidaemia guidelines to assess the management of high- and very high-risk cardiovascular (CV) patients requiring lipid-lowering therapy (LLT), at the ESC Congress 2021, organised by the European Society of Cardiology. SANTORINI is a multinational, prospective, observational, non-interventional study, primarily designed to document, in routine clinical practice, the effectiveness of current treatment options for managing levels of LDL-C in these patients.1,5

Results from the SANTORINI study, which has recruited 9,606 patients, show that at baseline, 18.6% of high- and very-high risk CV patients were not receiving any LLTs. The majority of patients (54.1%) received LLT as monotherapy, and combination LLT was only used in 27.3% of patients.1 The 2019 ESC/EAS management of dyslipidaemia guidelines recommend that the lower the levels of LDL-C for high- and very-high risk CV patients, the more their cardiovascular risk is reduced.2 Given that 80% of hypercholesterolaemia patients are not reaching guideline-recommended LDL-C goals, despite receiving LLTs, the SANTORINI findings reaffirm the need for more intensive use of LLTs.1

“LDL-C is a major modifiable risk factor for the prevention of heart attacks, strokes and other cardiovascular events that can lead to death. The SANTORINI study demonstrates the unmet need and why it is vital to rethink approaches to manage cholesterol levels in high- and very-high risk CV patients, specifically ensuring that these patients receive the most appropriate lipid-lowering therapies, in accordance with best practice, to help them achieve their target LDL-C goals,” said Professor Kausik Ray, Professor of Public Health and President of the European Atherosclerosis Society, Honorary Consultant Cardiologist, Head of Commercial Trials and Deputy Director of the Imperial Clinical Trials Unit at Imperial College London, and Principal Investigator of SANTORINI, who added, “There is a clear need for additional treatment options that are well tolerated, help patients meet their LDL-C goals and thus improve clinical outcomes.”

Contextual background: Simulation study data presented at ACC 2021 and published in the JACC anticipate a significant 10-year CV risk reduction when combination therapies are utilised

Earlier this year (May 2021), simulation data pooled from four completed pivotal randomised, double-blind, placebo-controlled, Phase 3 studies of bempedoic acid,6,7,8,9 were presented as a poster presentation at the American College of Cardiology’s (ACC) Scientific Session.10 The study which used the validated Second Manifestations of ARTerial disease (SMART) model, and has since been published in The Journal of the American College of Cardiology (JACC), predicted a reduction in CV risk in patients with atherosclerotic cardiovascular disease (ASCVD), if treated with bempedoic acid. The simulation study estimated that treatment with bempedoic acid on top of maximally tolerated statins would lead to a 3.3% absolute reduction in 10-year CV event risk compared with statins alone (p<0.0001).11 In patients who are intolerant to statins, the simulation predicted a 6.0% absolute reduction in 10-year CV event risk with bempedoic acid compared to placebo (p<0.0001).11 These results anticipate a significant risk reduction in CV events with bempedoic acid and reinforce the possible benefits of LDL-C lowering in high-risk patients with ASCVD.11

“Cardiovascular disease causes the death of more than four million people in Europe every year, hugely impacting families and the healthcare community,” said Dr Garth Virgin, Executive Director Medical Affairs, Specialty Medicines, at Daiichi Sankyo Europe. “At Daiichi Sankyo, we continue to invest in studies that bring relevant scientific information to the medical community to help inform clinical decision-making. Our goal is to help reduce CV risk for high- and very-high risk patients and, ultimately, reduce the impact of cardiovascular disease for people and healthcare systems across Europe.”

-ENDS-

About SANTORINI:
The SANTORINI study is a multinational, prospective, observational study that, to date, has enrolled more than 9,500 patients from over 800 sites in 14 countries across Europe.5 The primary objective is to document, in the real-world setting, the effectiveness of current treatment modalities in managing plasma levels of LDL-C in high- and very high-risk patients requiring lipid-lowering therapies. The study population consists of high- and very high-risk patients previously diagnosed and treated as well as newly diagnosed and requiring treatment.

Only data from routine clinical practice will be documented and physicians will not be required to perform any mandatory assessment outside the routine clinical practice. To facilitate accurate recording of data, patients can optionally fill in a memory aid to note important details. Data collection is estimated to finish in Q4 of 2021 with a final report of the study results estimated for Q4 of 2022.

About bempedoic acid
Bempedoic acid (commercialised in the European Economic Area, Turkey and Switzerland as NILEMDO®) is a first-in-class, oral treatment which lowers cholesterol, and which can be combined with other oral treatments to help lower cholesterol even further.12 Bempedoic acid inhibits ATP citrate lyase (ACL), an enzyme which is involved in the production of cholesterol in the liver.12

NILEMDO® has been approved for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:12

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

NILEMDO® acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to statin or other lipid-lowering therapies.12 Due to its unique mechanism of action, NILEMDO® is not activated in skeletal muscle.12

Daiichi Sankyo Europe has licensed exclusive commercialisation rights to NILEMDO® in the European Economic Area, Turkey and Switzerland from Esperion and is the full Marketing Authorisation Holder in these territories.

About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”

For more information, please visit www.daiichisankyo.com

References

This medicinal product is subject to additional monitoring.


1 Ray KK, et al. Treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe: baseline demographics from the multinational observational SANTORINI study. Poster 80441. Presented at ESC Congress 2021, August 2021.

2 The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemia. Eur Heart J. 2020 Jan 1;41(1):11 –188. doi:10.1093/eurheartj/ehz455.

3 Fox KM, et al. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018; 107: 380–388.

4 Kotseva K, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardio. 2019;26(8):824–835.

5 Ray KK, et al. Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study, Atherosclerosis Plus, 2021, https://doi.org/10.1016/j.athplu.2021.08.003

6 Ray KK, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019; 380:1022–32

7 Goldberg AC, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease. The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019; 322(18):1780–1788

8 Ballantyne CM, et al. Banach, M. Mancini, G.B.J. et al. Efficacy and Safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018 Oct; 277:195–203

9 Laufs U, et al. Banach, M. Mancini, G.B.J. et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019 Apr 2;8(7):e011662

10 Gunn L, et al. Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. 1056-13.Presented at ACC Congress 2021, August 2021.

11 Ray KK, et al. Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. JACC. 2021; 77 (18, Supplement 1). https://doi.org/10.1016/S0735-1097(21)02818-7

12 European Medicines Agency. NILEMDO® Summary of Product Characteristics. March 2020.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact
Dr. Wolfgang Schiessl
Daiichi Sankyo Europe GmbH
Director PR and Portfolio Communications, Specialty Medicines
+49 151 1714 7317

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Leaders in Cloud Adoption Approach Cloud Differently and Achieve 10x Greater ROI, Says Research by Wipro FullStride Cloud Services22.9.2021 18:24:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today released a report indicating that leaders in cloud adoption approach their cloud journey differently than beginners, enabling them to achieve a 10x greater annualized return on investment. Wipro’s report, “Making Business Thrive: A Cloud Leader Roadmap for Achieving 10x ROI,” outlines these best practices for enterprises beginning their cloud journey or seeking to accelerate their results. The report also identifies dozens of key cloud-adoption metrics for multiple industries and countries. Wipro FullStride Cloud Services developed the report based on a survey of 1,300 global C-level executives and key decision-makers from 11 industries and six countries (see “Methodology” below). Wipro considered leaders to be the top 19% of respondents based on cloud maturity, while beginners represented the lowest 32%; this was not based on revenue. Thi

Nathan's Famous Continues International Expansion with European Push to Offer Hot Dogs in France22.9.2021 17:57:00 CEST | Press release

Nathan's Famous, Inc., the American tradition serving New York favorites for more than 100 years, announces a new collaboration with Tommy's Diner, a 50's throwback American diner based in France, to offer its hot dogs in all locations across the country, making it the first time Nathan's Famous is served in France. This relationship continues Nathan's Famous growth in Europe and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210922005823/en/ Nathan's Famous Menu. (Photo: Business Wire) "Nathan's Famous is known the world over, which is why we've had such great success in recent years growing in the Middle East, Asia, and Great Britain," states James Walker, Senior Vice President, Restaurants. "This new relationship with Tommy's is a big step for us as we look to see that growth spread throughout Europe, and we're excited that they are our first French outpost and will be one of the first internationally to have our

IHMA Opens Microbiology Reference Laboratory in Shanghai, China to Further Support Global Anti-Infective Product Discovery and Development22.9.2021 16:30:00 CEST | Press release

IHMA has opened a microbiology reference laboratory in Shanghai, China in February of 2021. This facility will join IHMA locations in the USA, Switzerland and India to allow the company to provide more robust global support for anti-infective product discovery and development. The China facility will provide microbiology testing to support profiling of new antimicrobial products, antimicrobial resistance surveillance, molecular characterization of resistant organisms, and serve as a central laboratory for clinical trials conducted in China. “We have been working for almost 30 years to maximize our in vitro support for clients who are developing anti-infective products globally. Our facility in China will greatly enhance that effort and support clients wishing to conduct studies in this important market,” said Jack L. Johnson, President/CEO of IHMA. About IHMA: As the leading global microbiology service provider to the biopharmaceutical industry, IHMA utilizes its extensive laboratory a

Workiva Named a Leader Among Governance, Risk, and Compliance Platforms by Independent Research Firm22.9.2021 16:24:00 CEST | Press release

Workiva Inc. (NYSE:WK), today announced that it was classified as a Leader in The Forrester Wave™: Governance, Risk, and Compliance (GRC) Platforms Q3 2021 report. The company’s connected cloud platform enables collaboration and deep integration into existing systems and workstreams to simplify audit, risk and compliance, operational, financial, and non-financial reporting for companies across the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210922005704/en/ Workiva Named a Leader Among Governance, Risk, and Compliance Platforms by Independent Research Firm (Graphic: Business Wire) Evaluating GRC solutions against 25 criteria, Forrester identified 15 vendors available today, and proceeded to research, analyze, and score them. The report summarizes how each provider measures up, and ranks their solutions based on how well they satisfy the current and future needs of audit, risk, and compliance professionals. Workiva

The Scottish National Blood Transfusion Service (SNBTS) to Deploy Biolog-id Smart Storage RFID Kits Nationwide22.9.2021 15:50:00 CEST | Press release

The Scottish National Blood Transfusion Service (SNBTS) – the specialist provider of transfusion medicine in Scotland – will implement the biolog-id blood inventory devices to optimize the management of its blood products across the country. Through this deployment, biolog-id’s cutting-edge technology will streamline the complex inventory and distribution processes of the red blood cells to distant sites, enhancing the visibility and management of those lifesaving products between the Scottish blood centre and each remote blood bank. Designed for healthcare professionals specialized in the transfusion field, the Biolog Transfusion Solution combines RFID enabled devices powered by a proprietary IT engine and electronic labels. Biolog-id’s contactless devices are integrated into SNBTS’ IT transfusion management solution (MAK-SYSTEM – e-TRACELINE), offering real-time visibility of each component at each step of the supply chain. The corner-stone devices of this solution are the RFID Smart

Let’s Build a Digital Future Together: Join us at Dahua Partner Day 2021!22.9.2021 15:45:00 CEST | Press release

Dahua Technology, a world-leading video-centric smart IoT solution and service provider, will hold its 2nd online Dahua Technology Partner Day on October 13th - 14th with the theme “Building a digital future”. Adhering to its strategy of open cooperation, Dahua Technology is committed to creating a win-win ecosystem with leading technology partners around the world. This year, Dahua Technology will join hands with its 22 global partners to discuss interoperability, share industry trends, and explore the future of digitalization and intelligence together. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210922005395/en/ (Photo: Business Wire) “We are excited to host our second virtual technology partner day. Technologies have evolved fast in the past year, and the needs of digitization and diversified challenges facing different industries today are driving the integration of security companies,” says Mr. Jiaqi Gao, Overseas Ma

Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries22.9.2021 15:30:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the addition of four partnerships to its Global Corporate Social Responsibility (CSR) Program, which makes long-term commitments to strengthen health systems and improve access to healthcare for all in developing and emerging countries. As part of an annual decision-making process, Takeda employees worldwide voted to add IntraHealth International, Jhpiego, Pathfinder International and the World Food Programme(WFP) as new partners for the Global CSR Program, which now supports 20 programs in 72 countries. Takeda’s commitments to these new partners in FY2021 include: JPY 953 million to IntraHealth International to work with 12 private schools in Mali, Senegal and Niger to increase the number of qualified, trained nurses who can serve rural communities facing a critical shortage of health workers in these countries. Over the next five years, the project will help private schools partner with the public se

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom